Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Thursday, Aug 24, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Particularly, neratinib is showing progress in patients with HER2-positive hormone receptor-positive patients, as per results from the ExteNET trial.

SELECTED
LANGUAGE


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Particularly, neratinib is showing progress in patients with HER2-positive hormone receptor-positive patients, as per results from the ExteNET trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x